Healthleap Raises $38M to Flag At-Risk Hospital Patients for Review
Healthleap has raised $38 million in seed and Series A funding for an AI system that scans hospital records to flag patients who may have undiagnosed illness. The financing was detailed in reporting published on Oct. 7, 2026. TechCrunch
The funding splits into two rounds. The $8 million seed round was co-led by Sequoia Capital and First Round Capital. The $30 million Series A was led by Hummingbird Ventures. Healthleap is not disclosing its valuation.
Healthleap was founded in South Africa in 2022 by siblings Jemima and Josiah Meyer. Josiah Meyer serves as chief executive and co-founder.
The software connects to a hospital's electronic health record system, the central digital file where test results, orders and doctors' notes are stored. It uses language models, AI trained to read free text, to pull details from written notes alongside structured data such as lab values. The aim is to surface patients who may need a closer look from clinical staff.
Healthleap states its software does not diagnose patients. It only highlights cases for extra review. In current use, it screens for malnutrition and delirium. It is now live in more than 50 hospitals for those two uses.
The company grew from three hospital partners to more than 50 over the past year. Named customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. Revenue grew more than 10x over the same period. TechCrunch
Healthleap sells three-year contracts priced according to a hospital's licensed bed count.
The broader context here is fit rather than autonomy. The tool lives inside the existing record system and reads both notes and structured fields. It stops at flagging. For teams running clinical software and daily operations, that is easier to adopt than a separate diagnostic tool. Judgment stays with staff. The scope also stays narrow, with two conditions, one workflow and one integration point, which makes results easier to track and compare across sites.
In my view, the sales model is as important as the design. Three-year terms priced by bed count give both sides predictable costs. Hospitals can estimate spending without counting each software query. Healthleap can focus on steady use rather than per-click volume. If use holds across more than 50 sites, adding new conditions becomes mainly a question of data and testing rather than a new install. I have watched my own children pick up new tools without instructions, while hospitals adopt them only with proof. Healthleap is betting on that second path.
Looking further ahead, the benefit is practical. More patients get a second look who might be missed on a busy ward, and limited specialist time goes where review suggests it is most needed. For hospital software, modest claims that hold up in daily work are the ones that last.
